ISSUES LIMITED EDITION AQUA BLUE HAND NUMBERED AND SIGNED TO KICK OFF THEIR 2026 MISSION TO MARS TOUR. STOCKTON, NJ, ...
Nektar Therapeutics is rated Strong Buy based on promising Phase 2b maintenance data for REZPEG in atopic dermatitis. Click ...
Is NKTR stock a buy or a sell following this remarkable rally? We think it’s still worth exploring. However, before we delve ...
Nektar Therapeutics is basking in the honeyed glow of long-term phase 2 data for its immune asset rezpegaldesleukin in atopic ...
The results vaulted Nektar’s market value to over $1 billion amid expectations the drug might prove a challenger to widely ...
Nektar Therapeutics sees its stock nearly double after announcing positive Phase IIb data for its lead pipeline candidate, ...
Nektar Therapeutics (Nasdaq: NKTR) today announced an academic research collaboration with the University of California, San ...
With shares down more than 40% since November, the risk-reward for Nektar Therapeutics has shifted ahead of pivotal clinical trial results.
An eczema drug from Nektar Therapeutics maintained skin responses in a one-year study, meeting and in some cases exceeding ...
UCSF is teaming up with Nektar to study NKTR-0165, an experimental antibody that activates the TNFR2 receptor, as a treatment ...
Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) stock tumbled 6.9% in premarket trading Thursday after the clinical-stage biotechnology company announced the pricing of an upsized $400 million ...
Nektar Therapeutics (NKTR) stock jumps on positive mid-stage trial data for its experimental drug targeting atopic dermatitis. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results